HSCT is an established procedure for many acquired and congenital disorders of the hematopoietic system, including disorders of the immune system, and as enzyme replacement in metabolic disorders.
In 1990, the EBMT introduced the Activity Survey, a novel tool for assessing the real picture of HSCT in Europe. On an annual basis, all EBMT members and affiliated teams report their number of transplant patients by indication, donor type and stem cell source.
The Activity Survey has evolved into a mandatory self-reporting system and it forms an integral part of the international quality assurance programme JACIE. A second survey on cellular therapies and tissue engineering introduced in 2008 provides an overview of the latest developments in the field of non-HSCT cellular therapies. This coincides with the recent interest of the World Health Organization (WHO) in cell and tissue transplants, and further stresses the need for adequate and timely information. The analysis of the survey data spanning over 20 years has shown a continued and constant increase in the annual numbers of HSCT and transplant rates (number of HSCT per 10 million inhabitants) for both allogeneic and autologous HSCT.
This year report is based on the 2014 survey data. In addition to transplant rates and indications, this report focuses on the use of donors other than HLA identical siblings and matched unrelated donors for allogeneic HSCT.
A record number of 40,829 HSCT in 36,?469 patients were reported by 656 centers in 47 countries to the 2014 survey.
For more information, please read the orginal article: http://www.